Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy

Overview of attention for article published in JNCI: Journal of the National Cancer Institute, August 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (84th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 23 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 25 Dimensions

Readers on

mendeley: 45 Mendeley

Summary X Facebook Dimensions citations

So far, Dimensions has found 25 publications that cite this research output.

25

The most recent citing publications are shown below. View all 25 publications that cite this research output on Dimensions.

Abemaciclib pharmacology and interactions in the treatment of HR+/HER2− breast cancer: a critical review

Article in Therapeutic Advances in Drug Safety (April 2024)

Predicting drug–drug interactions in breast cancer patients treated with CDK4/6 inhibitors and forward planning

Article in Expert Opinion on Drug Metabolism & Toxicology (April 2024)

The impact of body mass index on the progression free survival of CDK 4/6 inhibitors in metastatic breast cancer patients

Preprint in Research Square (March 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.